Roche: names Genentech CEO to head pharmaceuticals unit

(CercleFinance.com) - Roche has named Bill Anderson, the current CEO of its biotechnology unit Genentech, to head its pharmaceuticals business as it expands its pipeline of medicines and faces digitalisation in healthcare.


The announcement comes as Daniel O'Day, who has been CEO of Roche Pharmaceuticals and member of the corporate executive committee, will be stepping down from his role as of 31 December 2018.

Before taking on new responsibilities elsewhere, O'Day will ensure a "smooth transition" until the end of February 2019, the Swiss drugmaker said.

Bill Anderson joined Roche in 2006, leading the immunology unit in Genentech. He was appointed Genentech's CEO in 2017.

Roche also said that it would propose Hans Clevers, a professor of molecular genetics at the University of Utrecht, in the Netherlands, for election to its board of directors at its next AGM scheduled for 5 March 2019.

Copyright (c) 2018 CercleFinance.com. All rights reserved.